Ascendia

  MARKET NEWS

Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington's Disease & Spinocerebellar Ataxia Types 1 & 3
Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology
WACKER, CordenPharma, LMU & HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives 
Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 & Atezolizumab in Hepatocellular Carcinoma
PDS Biotech Announces Plan to Initiate Phase 3 Study
Immutep Announces Expansion of Triple Combination Therapy in First Line Non-Small Cell Lung Cancer

  FEATURED EDITORIAL

  COMPANY PROFILE

As a partner for 17 out of 20 of the world’s leading medical device companies and brands, Porex engineers solve technical challenges for drug delivery products with custom-engineered high-quality components and resources designed specifically for the end device. Whether the drug delivery device is an inhaler, an injectable or a topical applicator, porous polymer technologies can be used for particle filtration, applicators, flow metering, fluid management, and sound diffusion. By combining our extensive material science expertise with our global manufacturing capability, we help our drug delivery customers find the perfect component to make their unique product design come to life. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra & PD-1 Inhibitor Tislelizumab for Patients With Solid Tumors

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra & PD-1 Inhibitor Tislelizumab for Patients With Solid Tumors

Enlivex Therapeutics Ltd. recently announced a clinical collaboration with BeiGene to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for….

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Inc. recently published a pivotal scientific paper in Aging Cell titled Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice with Dr. Hing C. Wong, the company’s Founder and CEO, as lead and….

SCYNEXIS & GSK Announce Exclusive Agreement to Commercialize & Further Develop Novel, First-in-Class Medicine to Treat Fungal Infection

SCYNEXIS & GSK Announce Exclusive Agreement to Commercialize & Further Develop Novel, First-in-Class Medicine to Treat Fungal Infection

SCYNEXIS, Inc. GSK plc recently announced they have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the….

Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs

Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs

Catalent recently announced the launch of the ProteoSuite Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.

Click here to …

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*

Summary

The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 12 – Formulation Development
April 19 – Prefilled Syringes